EBRAHIM HAZANY: Open Payments
NPI 1346359304 · NEWBURY PARK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,122 in 87 payments from 13 companies in 2025. Trend: 2023 $2,466 · 2024 $1,819 · 2025 $2,122
Food & beverage: $2,113Travel & lodging: $9
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $485 |
| ABBVIE INC. | 15 | $405 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $252 |
| Otsuka America Pharmaceutical, Inc. | 8 | $217 |
| Alkermes, Inc. | 9 | $165 |
| Axsome Therapeutics, Inc. | 9 | $163 |
| Lundbeck LLC | 5 | $130 |
| Bausch Health US, LLC | 5 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Tris Pharma Inc | 2 | $39 |
Products named: INGREZZA, VRAYLAR, REXULTI, CAPLYTA, ARISTADA, Auvelity, APLENZIN, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
